Analysis-Sanofi’s COVID-19 vaccine setback, drug pipeline cast long shadow

Published by

By Matthias Blamont PARIS (Reuters) – Pharmaceutical company Sanofi remains under pressure to launch new drugs and overcome setbacks in the COVID-19 vaccine race, despite a $3.2 billion deal to tighten its grip on promising mRNA technology. On Tuesday, Sanofi agreed to buy U.S. partner Translate Bio as it bets on next-generation vaccines and particularly as the French drugmaker, one of the world’s top flu vaccine makers, seeks to see off competition in one of its major markets. The two companies have been partnering since 2018 and are developing a COVID-19 mRNA shot together that has entered c…

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *